Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men
Tóm tắt
Race and ethnicity are important factors in health-related quality of life (QOL) because of racial differences in preferences for, and trust in, health systems. Such factors are likely to affect QOL and patient satisfaction with care. Using a self-reported questionnaire, Japanese men with prostate cancer reported lower sexual function scores at baseline. In detail, Japanese men were more likely than American men to report poor sexual desire, poor erection ability, poor overall ability to function sexually, poor ability to attain orgasm, poor quality of erections, infrequency of erections, infrequency of morning erections, and intercourse in the previous 4 weeks. However, Japanese men were less likely than American men to be concerned about their sexual function. Two years after surgery, American patients were more likely than Japanese patients to regain their baseline sexual function. The use of phosphodiesterase-5 (PDE-5) inhibitors has been widely publicized as the solution to erectile dysfunction after prostate cancer treatment. Although PDE-5 inhibitors have been available in Japan since 1999, it is striking that Japanese men with localized prostate cancer are much less likely (only 10%) to use PDE-5 inhibitors than American men. Japanese patients with localized prostate cancer report worse sexual function but are less concerned about their reduced function. In the absence of a biological explanation for such differences, however, we suspect that cultural differences may explain the differences between QOL survey results from Japanese or American men with prostate cancer.
Tài liệu tham khảo
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T. Comparative epidemiology of cancer between the United States and Japan. A second look. Cancer. 1991;67:746–63.
Penson DF, Chan JM. Urologic diseases in America project. Prostate cancer. J Urol. 2007;177:2020–9.
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37:S4–66.
Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29–33.
Litwin MS, Fitzpatrick JM, Fossa SD, Newling DW. Defining an international research agenda for quality of life in men with prostate cancer. Prostate. 1999;41:58–67.
Rose A, Peters N, Shea JA, Armstrong K. Development and testing of the health care system distrust scale. J Gen Intern Med. 2004;19:57–63.
Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, et al. Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol. 2004;22:4193–201.
Ramsey SD, Zeliadt SB, Hall IJ, Ekwueme DU, Penson DF. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol. 2007;177:1992–9.
Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7:3572–88.
Soloway CT, Soloway MS, Kim SS, Kava BR. Sexual, psychological and dyadic qualities of the prostate cancer ‘couple’. BJU Int. 2005;95:780–5.
Neese LE, Schover LR, Klein EA, Zippe C, Kupelian PA. Finding help for sexual problems after prostate cancer treatment: a phone survey of men’s and women’s perspectives. Psychooncology. 2003;12:463–73.
Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61:201–6.
Reynolds CF III, Frank E, Thase ME, Houck PR, Jennings JR, Howell JR, et al. Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a Brief Sexual Function Questionnaire for men. Psychiatry Res. 1988;24:231–50.
Derogatis LR, Melisaratos N. The DSFI: a multidimensional measure of sexual functioning. J Sex Marital Ther. 1979;5:244–81.
Rust J, Golombok S. The GRISS: a psychometric instrument for the assessment of sexual dysfunction. Arch Sex Behav. 1986;15:157–65.
Fineman KR, Rettinger HI. Development of the male function profile/impotence questionnaire. Psychol Rep. 1991;68:1151–75.
O’Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry MJ. A brief male sexual function inventory for urology. Urology. 1995;46:697–706.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–8.
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.
DeRogatis LR. Assessment of sexual function/dysfunction via patient reported outcomes. Int J Impot Res. 2008;20:35–44.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. J Impot Res. 1999;11:319–26.
Rosen RC, Cappelleri JC, Gendrano N III. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–44.
Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res. 2006;18:236–50.
Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178:597–601.
Hirsch M, Donatucci C, Glina S, Montague D, Montorsi F, Wyllie M. Standards for clinical trials in male sexual dysfunction: erectile dysfunction and rapid ejaculation. J Sex Med. 2004;1:87–91.
Hedgepeth RC, Labo J, Zhang L, Wood DP Jr. Expanded Prostate Cancer Index Composite versus Incontinence Symptom Index and Sexual Health Inventory for Men to measure functional outcomes after prostatectomy. J Urol. 2009;182:221–7.
Schroeck FR, Donatucci CF, Smathers EC, Sun L, Albala DM, Polascik TJ, Moul JW, Krupski TL. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008;113:2687–94.
Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17:307–19.
Cappelleri JC, Siegel RL, Glasser DB, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile dysfunction and the sexual health inventory for men. Clin Ther. 2001;23:1707–19.
Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology. 2000;56:477–81.
Ramanathan R, Mulhall J, Rao S, Leung R, Martinez Salamanca JI, Mandhani A, Tewari A. Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. J Sex Med. 2007;4:1336–44.
Moncada I, Micheltorena CF, Martínez-Sánchez EM, Gutiérrez JR. Evaluation of the psychometric properties of the life satisfaction checklist as a screening tool for erectile dysfunction. J Sex Med. 2008;5:83–91.
Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology. 2000;55:58–61.
Namiki S, Takegami M, Kakehi Y, Suzukamo Y, Fukuhara S, Arai Y. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer. J Urol. 2007;178:473–7.
Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, et al. Comparison of validated instruments measuring sexual function in men. Urology. 2010;76:380–6.
Hoffman RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med. 2003;18:845–53.
Namiki S, Kwan L, Kagawa-Singer M, et al. Sexual function reported by Japanese and American men. J Urol. 2008;179:245–9.
Litwin MS. Health related quality of life in older men without prostate cancer. J Urol. 1999;161:1180.
Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med. 1998;13:159–66.
Kakehi Y, Kamoto T, Ogawa O, Arai Y, Litwin MS, Suzukamo Y, et al. Development of Japanese version of the UCLA Prostate Cancer Index: a pilot validation study. Int J Clin Oncol. 2002;7:306–11.
Masumori N, Tsukamoto T, Kumamoto Y, Panser LA, Rhodes T, Girman CJ, et al. Decline of sexual function with age in Japanese men compared with American men—results of two community-based studies. Urology. 1999;54:344–5.
Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan: assessment by the International Index of Erectile Function. Int J Urol. 2001;8:53–9.
Shabsigh R, Perelman MA, Laumann EO, Lockhart DC. Drivers and barriers to seeking treatment for erectile dysfunction: a comparison of six countries. BJU Int. 2004;94:1055.
Uchida A, Bribiescas RG, Ellison PT, Kanamori M, Ando J, Hirose N, et al. Age related variation of salivary testosterone values in healthy Japanese males. Aging Male. 2006;9:207–13.
Hisasue S, Kumamoto Y, Sato Y, Masumori N, Horita H, Kato R, et al. Prevalence of female sexual dysfunction symptoms and its relationship to quality of life: a Japanese female cohort study. Urology. 2005;65:143–8.
Kakehi Y, Takegami M, Suzukamo Y, Namiki S, Arai Y, Kamoto T, et al. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. J Urol. 2007;177:1856–61.
Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO, GSSAB Investigators’ Group. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40–80 years in the urban population of Asian countries. BJU Int. 2005;95:609–14.
Moreira ED Jr, Brock G, Glasser DB, Nicolosi A, Laumann EO, Paik A, et al. Help-seeking behaviour for sexual problems: the global study of sexual attitudes and behaviors. Int J Clin Pract. 2005;59:6–16.
Schover LR, Fouladi RT, Warneke CL, et al. Seeking help for erectile dysfunction after treatment for prostate cancer. Arch Sex Behav. 2004;33:443–54.
Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–84.
Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162:433–8.
Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1999;54:503–8.
Namiki S, Kwan L, Kagawa-Singer M, Tochigi T, Ioritani N, Terai A, et al. Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. Prostate Cancer Prostatic Dis. 2008;11:298–302.
Catalona WJ, Basler JW. Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol. 1993;150:905–7.
Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164:1929–34.
Kundu SD, Roehl KA, Eggener SE, Antenor JAV, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004;172:2227–31.
Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239–47.
Hollenbeck BK, Dunn RL, Wei JT, Montie JE, Sanda MG. Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol. 2003;169:1453–7.
Namiki S, Ishidoya S, Ito A, Kawamura S, Tochigi T, Saito S, et al. Quality of life after radical prostatectomy in Japanese men: a 5-year follow up study. Int J Urol. 2009;16:75–81.
Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol. 2003;170:1291–4.
Descazeaud A, Debré B, Flam TA. Age difference between patient and partner is a predictive factor of potency rate following radical prostatectomy. J Urol. 2006;176:2594–8.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.
Shindel A, Quayle S, Yan Y, Husain A, Naughton C. Sexual dysfunction in female partners of men who have undergone radical prostatectomy correlates with sexual dysfunction of the male partner. J Sex Med. 2005;2:833–41.
Perez MA, Skinner EC, Meyerowitz BE. Sexuality and intimacy following radical prostatectomy: patient and partner perspectives. Health Psychol. 2002;21:288–93.
Raina R, Agarwal A, Goyal KK, Jackson C, Ulchaker J, Angermeier K, Klein E, Ciezki J, Zippe CD. Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology. 2003;62:1103–8.
Zippe CD, Jhaveri FM, Klein EA, Kedia S, Pasqualotto FF, Kedia A, Agarwal A, Montague DK, Lakin MM. Role of Viagra after radical prostatectomy. Urology. 2000;55:241–5.
Ohebshalom M, Parker M, Guhring P, Mulhall JP. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. J Urol. 2005;174:258–62.
Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, et al. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. J Urol. 2005;174:646–50.
Miller DC, Wei JT, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology. 2006;68:166–71.
Namiki S, Kwan L, Kagawa-Singer M, Arai Y, Litwin MS. The effect of erectile function on the use of phosphodiesterase-5 inhibitors after radical prostatectomy in Japanese and US men. Urology. 2008;71:901–5.
Perelman M, Shabsigh R, Seftel A, Althof S, Lockhart D. Attitudes of men with erectile dysfunction: a cross-national survey. J Sex Med. 2005;2:397–406.
Takahashi M, Kai I, Hisata M, Higashi Y. Attitudes and practices of breast cancer consultations regarding sexual issues: a nationwide survey of Japanese surgeons. J Clin Oncol. 2006;24:5763–8.
Gontero P, Fontana F, Bagnasacco A, Panella M, Kocjancic E, Pretti G, et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol. 2003;169:2166–9.
Wright JL, Lin DW, Cowan JE, Carroll PR, Litwin MS, CapSURE Investigators. Quality of life in young men after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008;11:67–73.
Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283:354–60.
Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer. 2002;95:2397–407.
Penson DF, Latini DM, Lubeck DP, Wallace K, Henning JM, Lue T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. J Urol. 2003;169:1458–61.